SGM-101 clinical trials
Also written SGM-101.
How each study uses SGM-101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SGM-101 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SGM-101
- 7
Studies by the year they started
8 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 6
Leiden University Medical Center (5) · Surgimab (2) · Sunil Singhal (1)
Studies
Open first, then newest update. How each study uses SGM-101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- SGM-101 in Colorectal Brain Metastases.RecruitingPhase 2Leiden University Medical CenterNCT04755920Written as SGM-101
- Fluorescence-guided Resection Of Colorectal Liver Metastases Using SGM-101 and Indocyanine GREENRecruitingPhase 2Leiden University Medical CenterNCT05965817Written as SGM-101 op top of ICG
- Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal CancerRecruitingPhase 3SurgimabNCT03659448Written as SGM-101
- SGM-101 Tumor Targeted Fluorescence Endoscopy in Rectal Polyps With Suspected T1 Adenocarcinoma or High Grade DysplasiaRecruitingPhase 2Leiden University Medical CenterNCT06280690Written as SGM-101
- Intraoperative Imaging of Pulmonary Nodules by SGM-101CompletedPhase 1Sunil SinghalNCT04315467Written as SGM-101
- SGM-101 in Colorectal Lung MetastasesStatus unknownPhase 2Leiden University Medical CenterNCT04737213Written as SGM-101
- SGM-101 in Locally Advanced and Recurrent Rectal CancerStatus unknownPhase 2/3Leiden University Medical CenterNCT04642924Written as SGM-101
- Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or PancreasCompletedPhase 1/2SurgimabNCT02973672Written as SGM-101